Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Velcade and intermittent Caelyx in platinum-resistant ovarian cancer
2005-003962-40Phase 2Completed
- Sponsor
- Fondazione SENDO
- Start
- Jan 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and pegylated liposomal doxorubicin in ovarian cancer and Oophoroma, sponsored by Fondazione SENDO. Started Jan 2007; status: completed.
02
Drugs
bortezomibpegylated liposomal doxorubicin
03
Conditions
ovarian cancerOophoroma
Beyond the preview
Go deeper on 2005-003962-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003962-40.